قائمة الدراسات السريرية المسجلة على الادوية

عنوان الدراسة	داعم الدراسة	حالة الدراسة	دواء الدراسة	مرحلة الدراسة	رقم بروتوكول الدراسة	موقع الدراسة
"Prospective Observational Clinical Practice Study in the 1st LineManagement of mCRC with Erbitux ™ in combination with Chemotherapy"	Merck Serono	Rejected	ERBITUX	4	EMR062202_	N/A
"A prospective, observational, non-randomized, European, multi-centerregistry, collecting REal-life information for the utilization of instantaneouswave-free ratio™ (iFR®) in Assessing coronary stenosis relevance in theMulti-vesseL disease patients population."	Volcano	Rejected	VOLCAO-iFR®	4	2014-CV-00	N/A
RETROSPECTIVE EPIDEMIOLOGY STUDY OF ALK REARRANGEMENT IN NON-SMALL CELL LUNG CANCER PATIENTS IN THE MIDDLE EAST & NORTH AFRICA	Pfizer	Rejected	-	4	A8081046	N/A
A Prospective, Longitudinal, Multinational, Observational Study to Describe Patterns of Care and Outcomes of Men who are at High Risk for Poor Clinical Outcomes after Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men with Castration-Resistant Prostate Cancer and Men with Metastatic Prostate Cancer at Initial Diagnosis	Astellas	Rejected			ONC-MA1001	N/A
An observational study to evaluate the effectiveness, safty and effect on health-related quality of life of treatment in routine practice (PERFORMS)	Novartis	Completed	Fingolimod	4	CFTY720D-MAX-TH-01	King Fahad Medical City (Riyadh), King Fahad Specialist Hospital (Dammam), King Faisal Specialist Hospital and Research Center (Jeddah)
"(LUMINOUS)Study to observe the effectiveness andsafety of ranibizumab through individualized patienttreatment and associated "	Novartis	Completed	Ranibizumab 10mg/ml (Lucentis)	4	RFB002A2406	King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah), Prince Sultan Military Medical City (Riyadh)
A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of KB195 in Subjects with a Urea Cycle Disorder with Inadequate Control on Standard of Care	Kaleido Biosciences	Ongoing	KB195	2	K020-218	King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Riyadh)
An observational, prospective, open-label to assess effectiveness, safety and tolerability of once-yearly treatment with zoledronic acid in osteoporotic patients in a real-world setting (AZURE).	Novartis	Completed	Zoledronic acid	4	CZOL446H-MAX-SA-01	King Fahad University Hospital (Al-Khobar), King Khalid University Hospital (Riyadh)
AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS	Roche	Terminated	Ocrelizumab	3b	MN39159	King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh)
A two part seamless, open label, multi-center study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type 1 spinal muscular atrophy.	Roche	Terminated	RO7034067	2	BP39056	King Faisal Specialist Hospital and Research Center (Riyadh)